I am excited to share that NanoRacks is releasing today our recent NASA-funded Low-Earth Orbit (LEO) Commercialization study. The LEO Commercialization Study came out of the Administration and NASA’s ...
The COBRA study is the first to compare an IL-17 receptor blocker with an IL-23 inhibitor in patients who do not respond adequately to an older biologic BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma ...
Low-Earth orbit (LEO) systems have emerged as a promising complement to GNSS, offering higher received power, better ...
- Based on the successfully completed single-dose part of the phase I clinical trial in Korean population carried out by JW Pharmaceutical, LEO Pharma files IND application to the FDA for study of ...
DELTA FORCE is the first head-to-head phase 3 trial comparing a systemic and investigational delgocitinib topical treatment for Chronic Hand Eczema (CHE). 1 TORONTO — LEO Pharma A/S, a global leader ...
In good news for patients living with chronic hand eczema (CHE), Leo Pharma – a company working to advance medical dermatology treatments – has unveiled positive topline results for its delgocitinib ...
Advertising agency Leo Burnett Australia has released part one of ‘The Good Study 2024’, in partnership with UTS Business School and Zenith Australia. The study found that while Australians ...
Precise positioning is increasingly critical for applications ranging from autonomous mobility to resilient infrastructure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback